TOPICAL DELIVERY OF DRUGS USING ETHOSOMES: A REVIEW

INDIAN DRUGS ◽  
2019 ◽  
Vol 56 (08) ◽  
pp. 7-20
Author(s):  
V Sankar ◽  
V. Wilson ◽  
K. Siram ◽  
A. Karuppaiah ◽  
S Hariharan ◽  
...  

The skin is the largest organ of the human body that restricts the movement of drug to the systemic circulation. Topical drug delivery system is a system where the drug reaches the systemic circulation through the protective layer i.e. skin. The main disadvantage of this route is the low diffusion rate of the drugs which is across the stratum corneum layer of the skin. To overcome this problem to a certain extent, ethosomal delivery for drugs and herbal compounds has been recently introduced. Literature studies indicate that ethosomal formulation of acyclovir shows high therapeutic efficiency with shorter healing time in the treatment of recurrent herpes labialis than conventional Zovirax. Also, the ethosomes of minoxidil enhanced the skin permeation of minoxidil in vitro in comparison to its ethanolic or phospholipid ethanolic micellar solution or hydroethanolic solution. T he advantages of this system include increased drug permeation, increased drug entrapment and improved drug delivery. Ethosomal drug delivery system opens up doors for the development of new and novel therapies for treating male pattern baldness, as it is an easier way to prepare, in addition to its safety and efficacy. In this review article, we have focused on methods of preparation of ethosomes, characterization techniques, applications, details about the various research trials for the management of androgenic alopecia and various ethosomal products in market.

2019 ◽  
Vol 11 (1) ◽  
pp. 55
Author(s):  
Shikha Baghel Chauhan ◽  
Tanveer Naved ◽  
Nayyar Parvez

Objective: The combination therapy of ethinylestradiol and testosterone in post-menopausal females has shown improved sexual response and libido. The present studies were designed to develop a suitable matrix-type transdermal drug delivery system (TDDS) of ethinylestradiol and testosterone using the polymer chitosan.Methods: Five formulations (ET1 to ET5) were developed by varying the concentration of polymer and keeping the drug load constant. Physical parameters and drug excipient interaction studies were evaluated in all the formulations. In vitro skin permeation profiles of ethinylestradiol and testosterone from various formulations were simultaneously characterized in a thermostatically controlled modified Franz Diffusion cell using HPLC. Based on the physical parameters and in vitro skin permeation profile formulation ET3 containing 30 mg/ml of chitosan was found to be the best and chosen for further studies. Optimized formulation was subjected to in vivo pharmacokinetic analysis in rats using ELISA.Results: Stability profile of patch formulation ET3 depicted stability up to 3 mo. One week skin irritation evaluation in rats indicated that formulation ET3 was nonirritating. Combination transdermal patch across rat skin showed a maximum release of 92.936 and 95.03 % in 60 h with a flux of 2.088 and 21.398 µg/cm2h for ethinylestradiol and testosterone respectively.Conclusion: The net result of this study is the formulation of a stable, non-irritating transdermal patch of ethinylestradiol and testosterone, with good bioavailability and can be used as Estrogen Replacement Therapy (ERT) in postmenopausal women.


2019 ◽  
Vol 9 (4) ◽  
pp. 521-538 ◽  
Author(s):  
Someshwar Komati ◽  
Suryakanta Swain ◽  
Muddana Eswara Bhanoji Rao ◽  
Bikash Ranjan Jena ◽  
Vishali Dasi

Innovations in pharmaceutical research are striving for designing newer drug therapies toeradicate deadly diseases. Strategies for such inventions always flourish with keys and objectivesof minimal adverse effects and effective treatment. Recent trends in pharmaceutical technologyspecify that mucoadhesive drug delivery system is particularly appropriate than oral controlrelease, for getting local systematic delivery of drugs in GIT for an extended interval of time ata predetermined rate. However, it is somehow expensive and unpleasant sensation for somepatients, but still it is needful for getting short enzymatic activity, simple administration withoutpain and evasion of fast pass metabolism. Usually the vehicles employed in drug delivery ofmucoadhesive system have a significant impact that draws further attention to potential benefitslike improved bioavailability of therapeutic agents, extensive drug residence time at the site ofadministration and a comparatively faster drug uptake into the systemic circulation. The drugrelease from mucoadhesive multiparticulates is contingent on several types of factors comprisingcarrier need to produce the multiparticles and quantity of medication drug contained in them.Mucoadhesion is characterized by selected theories and mechanisms. Various strategiesemergent in mucoadhesive multiparticulate drug delivery system (MMDDS) by in-vitro as wellas ex-vivo description and characterization are also critically discussed. Apart from these, theprimary focus during this review is to highlight current patents, clinical status, and regulatorypolicy for enhancement of mucoadhesive multi-particulate drug delivery system in the present scenario.<br />


2015 ◽  
Vol 7 (1-2) ◽  
pp. 65-74
Author(s):  
K. Latha ◽  
V. V. Srikanth ◽  
S. A. Sunil ◽  
N. R. Srinivasa ◽  
M. U. Uhumwangho ◽  
...  

The objective of this investigation is to study the applicability of gum karaya, the natural gum for the preparation and in vitro evaluation of losartan potassium, as Chronotherapeutic Drug Delivery System (ChDDS). The compression-coated timed-release tablets (CCT) containing losartan potassium in the core tablet were prepared by dry coating technique with different ratios of gum karaya as the outer coat. The parameters investigated were tensile strength, friability, in vitro dissolution studies and drug concentration. The optimized formulation was further characterized by powder XRD and FTIR to investigate interactions and no interactions observed. The tensile strength and friability of all the CCT were between 1.06-1.23 MN/m2 and < 0.3% respectively.  All the CCT showed a clear lag time before a burst release of drug. However, the lag time of drug release increased as the amount of gum karaya in the outer layer increased. For instance, the lag time of LGK1, LGK2, LGK3, LGK4, LGK5, LGK6 and LGK7 were 16, 10.5, 5.5, 3, 2, 1.5 and 0.5 hrs respectively.  The drug content of all the CCT was >98%. Formulation LGK3 was taken as an optimized formulation which can be exploited to achieve ChDDS of losartan potassium for the treatment of hypertension. 


2003 ◽  
Vol 92 (12) ◽  
pp. 2411-2418 ◽  
Author(s):  
Neslihan Gursoy ◽  
Jean‐Sebastien Garrigue ◽  
Alain Razafindratsita ◽  
Gregory Lambert ◽  
Simon Benita ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document